Evidence map›Paper›PMID 31144056›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2019

Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis.

Jae Hui Kim, Jong Woo Kim, Chul Gu Kim, Dong Won Lee

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04655482 (Treat-and-extend Using Aflibercept for Type 3 Neovascularization), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04655482 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Treat-and-extend Using Aflibercept for Type 3 Neovascularization

TypeinterventionalSponsorKim's Eye HospitalRan2021 to 2024Enrolled30ConditionsRetinal Angiomatous ProliferationArmsAflibercept Injection
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jae Hui KimDepartment of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, #156 Yeongdeungpo-dong 4-ga, Yeongdeungpo-gu, Seoul, 150-034, South Korea. kimoph@gmail.com.ORCID http://orcid.org/0000-0001-8121-6353
Jong Woo KimDepartment of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, #156 Yeongdeungpo-dong 4-ga, Yeongdeungpo-gu, Seoul, 150-034, South Korea.
Chul Gu KimDepartment of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, #156 Yeongdeungpo-dong 4-ga, Yeongdeungpo-gu, Seoul, 150-034, South Korea.
Dong Won LeeDepartment of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, #156 Yeongdeungpo-dong 4-ga, Yeongdeungpo-gu, Seoul, 150-034, South Korea.
Konyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the clinical significance of focal retinal pigment epithelium (RPE) atrophy in the eyes with type 3 neovascularization.

methodsThis retrospective study included 184 eyes those were diagnosed with type 3 neovascularization and were treated with antivascular endothelial growth factor (VEGF) therapy. Focal RPE atrophy was defined as a localized RPE atrophy found at the same location as the type 3 lesion. The incidence of reactivation after 3 loading injections and the visual outcomes was compared between a focal RPE atrophy group and a nonfocal RPE atrophy group. In the focal RPE atrophy group, the number of injections was compared between before and after the development of RPE atrophy.

resultsThe mean follow-up period was 37.6 ± 18.8 months; focal RPE atrophy developed in 24 eyes (13.0%). Reactivation of the lesion after 3 loading injections was significantly less frequent in the focal RPE atrophy group (58.3%) than that in the nonfocal RPE atrophy group (85.0%) (P = 0.004). In the focal RPE atrophy group, the mean best-corrected visual acuity (BCVA) was 0.68 ± 0.28 (Snellen equivalent = 20/95) at diagnosis and 0.70 ± 0.48 (20/100) at the final follow-up. In the nonfocal RPE atrophy group, the values were 0.75 ± 0.34 (20/112) and 1.12 ± 0.68 (20/263), respectively. The BCVA at the final follow-up was significantly better in the focal RPE atrophy group (P < 0.001). The mean number of injections per year was 4.9 ± 1.8 and 1.3 ± 1.6 before and after the development of focal RPE atrophy, respectively (P < 0.001).

conclusionsDevelopment of focal RPE atrophy was associated with a low incidence of reactivation of type 3 neovascularization and was therefore predictive of a favorable visual prognosis.

Indexed as

Visual AcuityAgedAngiogenesis InhibitorsAtrophyFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMalePrognosisRanibizumabRetinal DegenerationRetinal NeovascularizationRetinal Pigment EpitheliumAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AAge-related macular degenerationGeographic atrophyReactivationRetinal angiomatous proliferationType 3 neovascularization

Identifiers

PMID31144056
OpenAlexW2947786487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.